MedTrace Logo

Efficacy, Safety and Tolerability of Co-artemether in Non-immune Travelers

NCT00233337 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2012-04-27

No results posted yet for this study

Summary

This study will assess the safety and efficacy of co-artemether in the treatment of acute uncomplicated P. falciparum malaria in returning non-immune travellers

THIS STUDY IS NOT ENROLLING PATIENTS IN THE UNITED STATES

Conditions

  • Acute Uncomplicated P. Falciparum Malaria

Interventions

DRUG

Co-artemether

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-05-31
Primary Completion
2005-08-31
Completion
2005-08-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00233337 on ClinicalTrials.gov